linjc16/ctgov huggingface dataset:
A Study to Evaluate the Efficacy and of Stillen Tab. and to Demonstrate the Non-inferiority of Stillen Tab.

Study Overview
=================
Brief Summary
-----------------
This is a multicenter, active-controlled, randomized, double-blinded, paralleled group clinical study to evaluate the efficacy of 4-week treatment with Stillen tab. in patients with acute or chronic gastritis. Subject will receive Stillen tab or Mucosta tab., three times a day for four weeks.

Official Title
-----------------
A Multicenter, Active-controlled, Randomized, Double-blind Paralleled-group Clinical Trial to Evaluate the Efficacy of 4-week Treatment With Stillen Tab. in Patients With Acute or Chronic Gastritis

Conditions
-----------------
Acute Gastritis, Chronic Gastritis

Intervention / Treatment
-----------------
* Drug: Stillen Tab.
* Drug: Mucosta Tab.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age is over 20 years old, under 75 years old, men or women Patients diagnosed with acute or chronic gastritis by gastroscopy Patients with one or more erosions found by gastroscopy Signed the informed consent forms Exclusion Criteria: Patients with peptic ulcer and gastroesophageal reflux disease Patients administered with prokinetics, H2 receptor antagonists, proton pump inhibitors, anticholinergic drugs or non-steroid anti-inflammatory drugs prior to study in 2 weeks Patients with surgery related to gastroesophageal Patients with Zollinger-Ellison syndrome Patients with any kind of malignant tumor Patients administered with anti-thrombotic drugs Patients with significant cardiovascular, pulmonary, heptic, renal, hemopoietic or endocrine system primary disease Women either pregnant or breast feeding

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Stillen Tab.<br>administered three times daily for four weeks | Drug: Stillen Tab.<br> <br> |
| Active Comparator: Mucosta Tab.<br>administered three times daily for four weeks | Drug: Mucosta Tab.<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement rates of erosive gastritis | Improvement rates of erosive gastritis (%) = (improved cases)/(total cases administered) * 100 | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Healing rates of erosive gastritis | Healing rates of erosive gastritis (%) = (healed cases)/(total cases administered)*100 | 4 weeks | 
| Symptoms improved level |  | 4 weeks |
Technical Innovation Protocol for MR & US Plaque Imaging: Reproducibility.

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to develop non-invasive MRI, and MRS approaches that will quantify the plaque composition and lipid content of plaques and will have the potential for repeated in vivo measurements. Simultaneously this study aims to develop US plaque imaging as a screening tool to select plaque phenotypes of interest for clinical trials (a large LRNC). For plaque composition imaging by MRI the researchers aim to increase scan resolution and decrease scan time. For quantifying plaque lipid content the researchers aim to develop an MRS protocol. Subsequently, the researchers intend to study the reproducibility of plaque composition and lipid content measurements by MRI, MRS and Ultrasound in subjects that have carotid artery plaques.

Official Title
-----------------
Technical Innovation Protocol for Carotid Plaque Imaging by 3.0 Tesla MRI, MRS and Ultrasound: Reproducibility.

Conditions
-----------------
Atherosclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients, with 30 to 70% carotid artery stenosis on ultrasound duplex, who will not go for endarterectomy. Exclusion Criteria: Metal in the body, as a result of e.g. pacemaker or artificial cardiac valves; claustrophobia; surgery performed in the area of measurement (Carotid artery region); Cardiac arrhythmias.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with 30 to 70% carotid artery stenosis<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Efficacy of Narrative Exposure Therapy (NET) in Treating Women After Human Trafficking or Forced Prostitution

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to perform an evaluation of a trauma-focused short-term intervention (Narrative Exposure Therapy; Schauer, M., Neuner, F. & Elbert, T.) on a variety of clinical outcome measures (PTSD, Depression, Somatic Complaints, Dissociation) in women after sexual exploitation and women trafficking.

Official Title
-----------------
The Effectiveness of Narrative Exposure Therapy in Treating Women After Trafficking and Forced Prostitution

Conditions
-----------------
Posttraumatic Stress Disorder, Depression, Dissociation

Intervention / Treatment
-----------------
* Behavioral: Narrative Exposure Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sexual Exploitation or Women Trafficked or Forced Prostitution Symptoms of Post Traumatic Stress Disorder Exclusion Criteria: Current Psychotic Symptoms

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br> | Behavioral: Narrative Exposure Therapy<br>* Trauma-Focused short term intervention (8-12 sessions)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PTSD, Depression, Somatic Complaints, Dissociation |  | Pre-Test, 4-weeks-Post-Test, 6-months-follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Somatic Complaints
Energy Specific Far Infrared Radiation Treatment for AIDS

Study Overview
=================
Brief Summary
-----------------
The investigators are proposing that energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to enhance the immune system; thereby enhancing the production of killer cells to fight and destroy the human immunodeficiency virus.

Detailed Description
-----------------
Acquired immune deficiency syndrome or acquired immunodeficiency syndrome (AIDS or Aids) is a collection of symptoms and infections resulting from the specific damage to the immune system caused by the human immunodeficiency virus (HIV) in humans. The late stage of the condition leaves individuals prone to opportunistic infections and tumors. Although treatments for AIDS and HIV exist to slow the virus' progression, there is no known cure. The investigators are postulating that energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to enhance the immune system; thereby enhancing the production of CD4+ T cells and other killer cells to fight and destroy the human immunodeficiency virus. The primary end point is to determine the therapeutic effects of far infrared radiation (5μm to 20μm wavelength) on HIV/AIDS.

Official Title
-----------------
Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for HIV/AIDS

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Radiation: Far infrared


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1 Year and above Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 1<br>Infrared Radiation, wavelength between 5 and 20 microns | Radiation: Far infrared<br>* Far infrared radiation with the wavelength between 5μm and 20μm for 30 to 40 minutes per session.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary end point is to determine the therapeutic effects of far infrared radiation (5μm to 15μm wavelength) on HIV/AIDS. |  | One year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, AIDS, Radiation, Far infrared, Treatment, Acquired Immunodeficiency Syndrome, Complimentary therapies
Acute Pain Management Following Video-assisted Thoracoscopic Surgery: Comparison of Lobectomy and Wedge Resection

Study Overview
=================
Brief Summary
-----------------
Viedo-assisted thoracoscopic surgery(VATS) have became popular in recent years. There is no golden rule of postoperative analgesia for VATS. Compared with lobectomy, wedge resection preserves better pulmonary function and is suitable for elder patients and patients who could not afford to have lobectomy. In addition to surgery time、recovery time and hospital stay, wound incisions and organization damages are different,too. Will patients also have different response to pain control after these two surgery? The retrospective study is to compared the differences of postoperative pain management between VATS lobectomy and wedge resection.

Official Title
-----------------
Acute Pain Management Following Video-assisted Thoracoscopic Surgery: Comparison of Lobectomy and Wedge Resection

Conditions
-----------------
Postoperative Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >= 20 Using intravenous patient-controlled analgesia for postoperative analgesia ASA physical status classification I-III Exclusion Criteria: Staying in intensive care unit after surgery Emergency surgery Pregnancy Other surgery incisions which are not used for the video-assisted thoracoscopic surgery Patients never use intravenous patient-controlled analgesia after surgery

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative pain scale |  | postoperative day 1 to day 3 |
Comparison of Respiratory Muscle, Pain, Functional Performance and Cognitive Status in Obstructive Lung Diseases

Study Overview
=================
Brief Summary
-----------------
In the literature, there are a limited number of studies evaluating postural awareness, cognitive status, respiratory muscle strength and endurance, functional capacity, and pain in people with obstructive pulmonary disease, and comparing these parameters with each other and with healthy subjects, and most of the studies are on chronic obstructive pulmonary disease patients. There we will evaluate these parameters in different obstructive lung diseases and compare the findings of healthy individuals.

Official Title
-----------------
Assessment of Cognitive Status, Pain, Functional Status, Postural Awareness, Respiratory Muscle Strength and Endurance in Obstructive Pulmonary Diseases

Conditions
-----------------
Pain, Chronic, Obstructive Pulmonary Disease, Cognitive Impairment, Functional Disturbance

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for obstructive lung diseases To be diagnosed with obstructive pulmonary disease, Have not experienced acute exacerbation in the last 3 months, Being between the ages of 18-65, Not having chronic pain problems, Volunteer for research, To be able to walk and cooperate. Exclusion criteria for obstructive lung diseases To be able to diagnose neurological disorder, To have an advanced orthopedic disease that may affect functional capacity measurement. Criteria for Non-Inclusion for healthy group To have any cardiopulmonary disease, To have an advanced orthopedic disease that may affect functional capacity measurement.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Obstructive lung diseases group<br> | |
| Healthy group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain Perception | Pain Perception Threshold and Tolerance With Algometer | 01.01.2019-31.08.2019 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognitive Function Assessment | Montreal Cognitive Assessment Test (MoCA) | 01.01.2019-31.08.2019 | 
| Functional capacity assesment | 6 minute walk test | 01.01.2019-31.08.2019 | 
| Postural awareness assesment | Body Awareness Questionnare is a likert type questionnare and total score ranges from 18-126. Higher scores mean better body awareness level | 01.01.2019-31.08.2019 | 
| Respiratory muscle strength and endurance measurement | Mouth pressure measurement | 01.01.2019-31.08.2019 |
Study to Compare Pharmacokinetic Characteristics of Eperisone and Aceclofenac With NVP-1203

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the pharmacokinetics of NVP-1203 and coadministration of aceclofenac and eperisone HCl SR.

Detailed Description
-----------------
aceclofenac and eperisone(low back pain)

Official Title
-----------------
Partial Replicated Crossover Clinical Study to Compare Pharmacokinetic Characteristics of Eperisone and Aceclofenac With NVP-1203 Treatment to Those of Co-administration of Eperisone Hydrochloride Slow Release and Aceclofenac in Volunteers

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: NVP-1203
* Drug: Eperisone SR tab. + and Airtal tab.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male volunteers, age between 19 and 45 BMI of >19kg/m2 and <28kg/m2 subject Informed of the investigational nature of this study and voluntarily agree to participate in this study Exclusion Criteria: Use of any prescription medication within 14 days prior to Day 1 Use of any medication within 7 days prior to Day 1

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: NVP-1203<br>NVP-1203 | Drug: NVP-1203<br>* NVP-1203(eperisone SR + aceclofenac)<br>* Other names: Eperisone SR + aceclofenac;|
| Active Comparator: Eperisone SR tab. + and Airtal tab.<br>Eperisone HCl and aceclofenac | Drug: Eperisone SR tab. + and Airtal tab.<br>* Eperisone SR and aceclofenac<br>* Other names: Eperisone SR tab + airtal tab.;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area Under Curve(AUC) last |  | 0-24hr |
Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure

Study Overview
=================
Brief Summary
-----------------
This is a randomized, double-blind, placebo-controlled, dose ranging pilot study to examine the effects of conivaptan in patients with acute decompensated heart failure.

Official Title
-----------------
A Randomized, Double-blind, Placebo-controlled, Dose-ranging Pilot Study Evaluating the Efficacy and Safety of YM087 in Patients With Decompensated Chronic Heart Failure

Conditions
-----------------
Chronic Heart Failure

Intervention / Treatment
-----------------
* Drug: conivaptan
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients may be male or female age 18 years or older. Women must be post-menopausal or surgically sterile. Patients must have chronic heart failure of at least 2 months duration and be hospitalized for the treatment of worsening heart failure. The primary manifestation of worsening heart failure must be worsening dyspnea.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 1<br> | Drug: placebo<br>* IV<br>|
| Experimental: 2<br>Low dose | Drug: conivaptan<br>* IV<br>* Other names: YM087;|
| Experimental: 3<br>Middle dose | Drug: conivaptan<br>* IV<br>* Other names: YM087;|
| Experimental: 4<br>High dose | Drug: conivaptan<br>* IV<br>* Other names: YM087;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in respiratory Visual analog Scale (VAS) |  | 48 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in global VAS |  | 48 hours | 
| Total urine output vs. baseline |  | 72 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Heart Failure, YM078
Glycemic Control in Diabetic Hospitalized Patients

Study Overview
=================
Brief Summary
-----------------
With the advanced management of diabetes and new innovative anti-hyperglycemic therapy hyperglycemia remains a culprit factor affecting the outcome of patients admitted to the hospital in general wards. Efforts from health care providers to assess and control blood sugar by a simplified method such as certified point of care hand-sized glucometers is the fruitful protocol if the results near the target that is endorsed by well-known diabetes societies. In non-critically patients the premeal blood sugar ≤140 mg /dl and ≤ 180 mg /dl after a meal. The unstable economy and political crises with the pandemic of Covid-19 making us use a glucometer to monitor and control the fluctuation of blood sugar in order to decrease the burden on the patients and health care providers in the form of a stay in the hospital and minimize wasting laboratory resources.

Official Title
-----------------
Glycemic Control in Diabetic Hospitalized Patients: a Cross Sectional Study

Conditions
-----------------
Diabetes, Diabetes Mellitus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: admitted to the hospital Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| glycemic control | percentage of patients with glucose measurement (Random Blood Sugar, RBS, Fasting Blood Sugar, FBS) between 140-180 measured with bedside glucometers preferably before meals and at 6 am for fasting blood sugars or as directed by the physician | From hospital admission to hospital discharge for a median of 7 days and up to 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| average blood glucose value per ward | average blood glucose value per ward (medical vs. surgical vs ICU/CCU | From hospital admission to hospital discharge for a median of 7 days and up to 1 month | 
| average per patient | average blood glucose levels per patient | From hospital admission to hospital discharge for a median of 7 days and up to 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diabetes mellitus, hyperglycemia, glycemic control, inpatient